Abeona Therapeutics Inc. (LON: 0H7R)
London
· Delayed Price · Currency is GBP · Price in USD
5.17
+0.01 (0.23%)
Jan 23, 2025, 3:52 PM BST
Abeona Therapeutics Revenue
In the year 2023, Abeona Therapeutics had annual revenue of $3.50M USD with 147.52% growth.
Revenue
$3.50M
Revenue Growth
+147.52%
P/S Ratio
n/a
Revenue / Employee
$41.67K
Employees
84
Market Cap
181.42M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Abeona Therapeutics News
- 23 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 2 months ago - Abeona Therapeutics® Announces Participation in November Investor Conferences - GlobeNewsWire
- 2 months ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration - GlobeNewsWire
- 4 months ago - Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy - Seeking Alpha
- 5 months ago - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewsWire